Conundrums in community-acquired pneumonia

Patrick G P Charles, Paul D R Johnson and M Lindsay Grayson
Med J Aust 2006; 185 (3): . || doi: 10.5694/j.1326-5377.2006.tb00496.x
Published online: 7 August 2006

Clinically useful CAP management guidelines are still elusive

Community-acquired pneumonia (CAP) continues to generate controversy. Although CAP is common and generally mild, it can be life-threatening. For the treating clinician there are many questions. How much effort should be directed to establishing the aetiology, given that the responsible pathogen is infrequently diagnosed? Should the patient be managed in hospital or at home? Should one choose older, established antibiotics that work most of the time or broad-spectrum therapy that treats all imaginable pathogens but is probably unnecessary, has a less established safety record and is likely to contribute to increased cost of treatment and the emergence of resistance?

  • Patrick G P Charles1,2
  • Paul D R Johnson1,2
  • M Lindsay Grayson1,2,3

  • 1 Department of Infectious Diseases, Austin Health, Melbourne, VIC.
  • 2 Department of Medicine, University of Melbourne, Melbourne, VIC.
  • 3 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.